Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer — Stella

Home/Primary Liver Cancer/Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

View on ClinicalTrials.gov

Recruiting

Back to Primary Liver Cancer trials

Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang

Key details

Phase

Early testing

Sponsor

CNBG-Virogin Biotech (Shanghai) Ltd.

Enrollment target

~44 participants

Started

March 2021

Primary completion

March 2022

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated September 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.